Paul Strumph
Overview
Explore the profile of Paul Strumph including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
543
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bode B, Cengiz E, Wadwa R, Banks P, Danne T, Kushner J, et al.
Diabetes Technol Ther
. 2020 Jul;
23(1):59-69.
PMID: 32640846
Young adults with type 1 diabetes (T1D) tend to have higher A1C than older adults and are at increased risk for diabetic ketoacidosis (DKA). Oral adjuncts to insulin have not...
2.
Powell D, Zambrowicz B, Morrow L, Beysen C, Hompesch M, Turner S, et al.
J Clin Endocrinol Metab
. 2019 Dec;
105(4).
PMID: 31837264
Context: The effect of sotagliflozin (a dual sodium-glucose cotransporter [SGLT] 2 and SGLT1 inhibitor) on intestinal glucose absorption has not been investigated in humans. Objective: To measure rate of appearance...
3.
Baker C, Wason S, Banks P, Sawhney S, Chang A, Danne T, et al.
Diabetes Obes Metab
. 2019 Jul;
21(11):2440-2449.
PMID: 31264767
Aims: To assess the dose-related effects of sotagliflozin, a novel dual inhibitor of sodium-glucose co-transporters-1 and -2, in type 1 diabetes (T1D). Materials And Methods: In this 12-week, multicentre, randomized,...
4.
Danne T, Cariou B, Buse J, Garg S, Rosenstock J, Banks P, et al.
Diabetes Care
. 2019 Mar;
42(5):919-930.
PMID: 30833371
Objective: To evaluate effects of the dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibitor sotagliflozin in combination with insulin on glucose time in range (TIR) and glucose excursions, postprandial glucose...
5.
Danne T, Cariou B, Banks P, Brandle M, Brath H, Franek E, et al.
Diabetes Care
. 2018 Jun;
41(9):1981-1990.
PMID: 29937431
Objective: The objective of this study was to evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 and 2 inhibitor sotagliflozin compared with placebo when combined with optimized...
6.
Buse J, Garg S, Rosenstock J, Bailey T, Banks P, Bode B, et al.
Diabetes Care
. 2018 Jun;
41(9):1970-1980.
PMID: 29937430
Objective: Evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes (T1D). Research Design And...
7.
8.
Garg S, Henry R, Banks P, Buse J, Davies M, Fulcher G, et al.
N Engl J Med
. 2017 Sep;
377(24):2337-2348.
PMID: 28899222
Background: In most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of...
9.
Sands A, Zambrowicz B, Rosenstock J, Lapuerta P, Bode B, Garg S, et al.
Diabetes Care
. 2015 Jun;
38(7):1181-8.
PMID: 26049551
Objective: To assess the safety and efficacy of dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibition with sotagliflozin as adjunct therapy to insulin in type 1 diabetes. Research Design And...
10.
Lapuerta P, Zambrowicz B, Strumph P, Sands A
Diab Vasc Dis Res
. 2015 Feb;
12(2):101-10.
PMID: 25690134
The sodium-dependent glucose transporter 2 (SGLT2) inhibitors are an important emerging class for the treatment of diabetes. Development of SGLT2 inhibitors has been oriented around a desire for high selectivity...